PPT-Extended Anticoagulation in VTE

Geoffrey Barnes MD Cardiovascular and Vascular Medicine University of Michigan USA 1 st Qatar Conference on Safe Anticoagulation Management February 27 2015 Outline VTE Recurrence Risk. Updates and Clarification to the Process. This NetLearning is meant to clarify common confusion regarding the VTE Prophylaxis Process. . If you did not attend a Meaningful Use Class or take the original NetLearning, “Meaningful Use Mandatory NetLearning”, please view both to ensure that you understand the process completely!. how long to treat?. Eliot Williams, MD PhD. Department of Medicine. Division of Hematology & Medical Oncology. 3 months of anticoagulant treatment is both necessary and sufficient for most patients after a first episode of VTE. Fibrillation. Michelle Tsukamoto . DSR 2 May 9, 2018. PGY 2. 1. Objectives. Discuss which patients with . atrial. fibrillation should be . anticoagulated. for CVA prevention. Learn about different oral anticoagulation options . Fibrillation. Michelle Tsukamoto . DSR 2 May 9, 2018. PGY 2. 1. Objectives. Discuss which patients with . atrial. fibrillation should be . anticoagulated. for CVA prevention. Learn about different oral anticoagulation options . Judicious Use of Anticoagulation: A Case-Based Approach Michael B. Streiff, MD, FACP Associate Professor of Medicine and Pathology Division of Hematology Medical Director, Johns Hopkins Anticoagulation Management Service and Outpatient Clinics Presented by. Faculty/Presenter Disclosure. Faculty:. Relationships with commercial interests:. Disclosure of Commercial Support. This program has received financial support from Sanofi Canada, in the form of an educational grant.. Pregnancy for women with complex needs. Maternity service update. Antenatal VTE assessment. Dr Lauren Ward – CCG clinical lead for preconception and antenatal care. Background – venous thromboembolism. Geoffrey Barnes, MD, MSc. University of Michigan. @. GBarnesMD. May 14, 2020. Disclosures. Grants: Pfizer/Bristol-Myers Squibb, Blue Cross Blue Shield of Michigan, NHLBI, AHRQ. Consulting: Pfizer/Bristol-Myers Squibb, Janssen, Portola, AMAG Pharmaceuticals. An Educational Slide Set . American Society of Hematology 2018 Guidelines . for Management of Venous Thromboembolism. Slide set authors: . E. ric. Tseng MD, . MScCH. , University of Toronto and . Paul . Dr Henan Dh Skheel. Department Of . Obs&Gyn. 2020. Venous . thromboembolism.  (. VTE) is a collective term that describes deep vein thrombosis (DVT) and pulmonary embolism (PE).. Venous thromboembolism is a leading cause of . and Pulmonary Embolism. An Educational Slide Set . American Society of Hematology 2020 Guidelines for Management of Venous Thromboembolism. Slide set authors: . Zachary . Liederman. MD . MScCH. (University of Toronto). Educational Slides Set. American Society of Hematology 2021 . Authors: . Mario Luis Tejerina Valle, MD, . Caja. . Petrolera. de . Salud. - Bolivia. Juan Carlos Serrano Casas, MD, Universidad Central de Venezuela . introduction. Twenty percent of maternal deaths in the United States during that period were attributed to PE.. . Inherited . thrombophilias. are associated with an increased risk of venous . thromboembolism. An Educational Slide Set . American Society of Hematology 2020 Guidelines . for Management of Venous Thromboembolism. Slide set author: . Siraj . Mithoowani. MD, MHPE (McMaster University). Clinical Guidelines.